A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
Phase 1
Recruiting
- Conditions
- Relapsed/refractory multiple myeloma, Amyloid light-chain amyloidosisMedDRA version: 23.0Level: LLTClassification code: 10083938Term: Amyloid light-chain amyloidosis Class: 10021428MedDRA version: 25.0Level: LLTClassification code: 10086466Term: Relapsed/refractory multiple myeloma Class: 100000004848Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-502057-33-00
- Lead Sponsor
- Sanofi-Aventis Recherche & Developpement
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 105
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method